Revumenib: a Novel Menin-MLL1 Inhibitor in Ph. II for AML

revumenib

oral menin-KMT2A inhibitor Ph. I/II for r/r leukemia, CRC & solid tumors discovery not disclosed Nature, March 15, 2023 Vitae, Madison, NJ / Syndax, Waltham, MA

Drug Hunter Team

revumenib, oral menin-KMT2A inhibitor, Ph. I/II for r/r leukemia, CRC & solid tumors, discovery not disclosed, Nature, March 15, 2023, VITAE, MADISON, NJ / SYNDAX, WALTHAM, MA

Revumenib: a Novel Menin-MLL1 Inhibitor in Ph. II for AML

revumenib

Other molecules you may be interested in